Russia’s Sputnik V developers call on AstraZeneca to try combining vaccines

A handout photograph provided by the Russian Direct Investment Fund (RDIF) shows samples of a vaccine against coronavirus virus (COVID-19) developed by Gamalaya Research Institute of Epidemiology and Microbiology on August 6, 2020 in Moscow, Russia.

Russian Direct Investment Fund | Reuters

Developers of the Sputnik V COVID-19 vaccine said on Thursday that AstraZeneca should try to combine its experimental shot with Russian to increase efficacy.

According to the results of the interim trial, Russia stated that its Sputnik V vaccine is 92% effective in protecting people from COVID-19, while AstraZeneca stated that its COVID-19 vaccine was 70% effective and up to 90% effective. Can.

The developers of the Russian vaccine said on their Twitter account, “If they go for a new clinical trial, we suggest trying to combine AZ shot with #SputnikV human adenoviral vector shot.”

“Combination of vaccines may prove important for vaccination.”

AstraZeneca has stated that by the end of 2020 it will have a total of 200 million doses of the vaccine.

The British developed vaccine is seen as one of the best expectations for many developing countries because of its affordable price and ability to be carried at normal fridge temperatures.

With 2,187,990 infections, Russia has the fourth highest number of COVID-19 cases behind the United States, India and Brazil.

AstraZeneca is likely to run an additional global trial to assess the efficacy of its vaccine, its chief executive Pascal Sorriot said by Bloomberg News, questioning the results from its late-stage study.

The British government’s chief scientific adviser, Patrick Valence, said the main thing about the AstraZeneca vaccine was that it worked when asked about these doubts.

“The title result is the work of the vaccine and is very exciting,” Valence said during a news briefing with British Prime Minister Boris Johnson.

Related Posts